|
Match
|
Document |
Document Title |
|
|
US20140057934 |
METHYLNALTREXONE NASAL FORMULATIONS, METHODS OF MAKING, AND USE THEREOF
Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are... |
|
|
US20150258045 |
INTRAVENOUS ADMINISTRATION OF TRAMADOL
A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is... |
|
|
US20130230596 |
Abuse-Resistant Oral Dosage Forms And Method Of Use Thereof
An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but... |
|
|
US20150231086 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the... |
|
|
US20140371256 |
PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and... |
|
|
US20110160239 |
ORAL ADMINISTRATION OF PERIPHERALLY-ACTING OPIOID ANTAGONISTS
Peripherally-acting opioid antagonists can be orally administered to treat the side effects of opioid administration in convenient dosing schedules. |
|
|
US20110123517 |
DISSOLVABLE PHARMACEUTICAL IMPLANT
A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after... |
|
|
US20150182467 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Methods of decreasing abuse potentials of oral opioid dosage forms are described. In the methods, an opioid antagonist in a substantially non-releasable form is included in oral dosage forms... |
|
|
US20130197020 |
Method of Providing Sustained Analgesia With Buprenorphine
A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum... |
|
|
US20110288112 |
Method of Providing Sustained Analgesia With Buprenorphine
A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum... |
|
|
US20110071181 |
EFFERVESCENT ORAL OPIATE DOSAGE FORMS AND METHODS OF ADMINISTERING OPIATES
Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended... |
|
|
US20100317682 |
Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt
The use of methylnaltrexone bromide in combination and in one dosage unit, with any opioid drug in order to prevent the constipation which can be associated with opioids. |
|
|
US20110020450 |
TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM
The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are... |
|
|
US20140322311 |
CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20140112984 |
Crush resistant delayed-release dosage forms
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20140079780 |
Crush resistant delayed-release dosage forms
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20140322318 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20110059170 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20120041014 |
Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia
A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release... |
|
|
US20140112989 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with... |
|
|
US20130251643 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with... |
|
|
US20110178114 |
TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY
A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the... |
|
|
US20140296276 |
SEQUESTERED ANTAGONIST FORMULATIONS
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is... |
|
|
US20140099376 |
SEQUESTERED ANTAGONIST FORMULATIONS
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is... |
|
|
US20130251812 |
SEQUESTERED ANTAGONIST FORMULATIONS
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is... |
|
|
US20100316678 |
COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN
The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that... |
|
|
US20110086874 |
Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia
A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release... |
|
|
US20110086873 |
Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia
A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release... |
|
|
US20130210853 |
Injectable Flowable Composition Comprising Buprenorphine
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to... |
|
|
US20140316333 |
DISSOLVING SOLID SOLUTION PERFORATOR PATCH FOR MIGRAINE TREATMENT
A dissolving solid solution perforator (SSP) patch for oral cavity administration may include at least one perforator. The at least one perforator may contain a first drug and be configured to... |
|
|
US20140080857 |
METHODS FOR PROPHYLATIC APPETITE SUPPRESSION
Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to... |
|
|
US20150209315 |
ADMINISTRATION OF INTRAVENOUS IBUPROFEN
An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the... |
|
|
US20130142781 |
PEG BASED HYDROGEL FOR PERIPHERAL NERVE INJURY APPLICATIONS AND COMPOSITIONS AND METHOD OF USE OF SYNTHETIC HYDROGEL SEALANTS
Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic... |
|
|
US20140099369 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. |
|
|
US20130251789 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. |
|
|
US20120288565 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. |
|
|
US20110097404 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. |
|
|
US20070191412 |
Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically... |
|
|
US20110318345 |
NASAL DELIVERY
substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of... |
|
|
US20130142882 |
METHODS AND COMPOSITIONS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF BONE CANCER PAIN
The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds. |
|
|
US20110092482 |
METHODS AND COMPOSITIONS
The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of... |
|
|
US20120015031 |
NOVEL GASTRO-RETENTIVE DOSAGE FORMS
A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least... |
|
|
US20110171325 |
Systems and Methods for Treating Pain Using Brain Stimulation
The invention comprises systems and methods for treating nociceptive pain including at least one force-regulatable device in mechanical, electrical, or chemical communication with at least one... |
|
|
US20120189693 |
ORAL DOSAGE FORMS
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0... |
|
|
US20120083505 |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
The present invention is directed to an opioid receptor antagonist or a pharmaceutically acceptable salt thereof for use in a method of acute treatment of paraphilic sexual arousal states in... |
|
|
US20110171323 |
METHODS AND KITS TO PREDICT PROGNOSTIC AND THERAPEUTIC OUTCOME IN SMALL CELL LUNG CANCER
Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the... |
|
|
US20130317049 |
Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition
Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions... |
|
|
US20110150766 |
Transdermal patch with fatal overdose protection
A transdermal patch having a top region containing an antagonist followed by a bottom region containing an agonist, whereby the bottommost end of the bottom region is secured to the skin of the... |
|
|
US20150141451 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The... |
|
|
US20110237563 |
FAST DISSOLVING DRUG DELIVERY SYSTEMS
The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition,... |